Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

90 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PTEN Loss Confers Resistance to Anti-PD-1 Therapy in Non-Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells.
Exposito F, Redrado M, Houry M, Hastings K, Molero-Abraham M, Lozano T, Solorzano JL, Sanz-Ortega J, Adradas V, Amat R, Redin E, Leon S, Legarra N, Garcia J, Serrano D, Valencia K, Robles-Oteiza C, Foggetti G, Otegui N, Felip E, Lasarte JJ, Paz-Ares L, Zugazagoitia J, Politi K, Montuenga L, Calvo A. Exposito F, et al. Among authors: lozano t. Cancer Res. 2023 Aug 1;83(15):2513-2526. doi: 10.1158/0008-5472.CAN-22-3023. Cancer Res. 2023. PMID: 37311042
SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.
Redin E, Garmendia I, Lozano T, Serrano D, Senent Y, Redrado M, Villalba M, De Andrea CE, Exposito F, Ajona D, Ortiz-Espinosa S, Remirez A, Bertolo C, Sainz C, Garcia-Pedrero J, Pio R, Lasarte J, Agorreta J, Montuenga LM, Calvo A. Redin E, et al. Among authors: lozano t. J Immunother Cancer. 2021 Mar;9(3):e001496. doi: 10.1136/jitc-2020-001496. J Immunother Cancer. 2021. PMID: 33658304 Free PMC article.
Short-term starvation reduces IGF-1 levels to sensitize lung tumors to PD-1 immune checkpoint blockade.
Ajona D, Ortiz-Espinosa S, Lozano T, Exposito F, Calvo A, Valencia K, Redrado M, Remírez A, Lecanda F, Alignani D, Lasarte JJ, Macaya I, Senent Y, Bértolo C, Sainz C, Gil-Bazo I, Eguren-Santamaría I, Lopez-Picazo JM, Gonzalez A, Perez-Gracia JL, de Andrea CE, Vicent S, Sanmamed MF, Montuenga LM, Pio R. Ajona D, et al. Among authors: lozano t. Nat Cancer. 2020 Jan;1(1):75-85. doi: 10.1038/s43018-019-0007-9. Epub 2020 Jan 13. Nat Cancer. 2020. PMID: 35121837
Expansion of Tumor-Infiltrating CD8+ T cells Expressing PD-1 Improves the Efficacy of Adoptive T-cell Therapy.
Fernandez-Poma SM, Salas-Benito D, Lozano T, Casares N, Riezu-Boj JI, Mancheño U, Elizalde E, Alignani D, Zubeldia N, Otano I, Conde E, Sarobe P, Lasarte JJ, Hervas-Stubbs S. Fernandez-Poma SM, et al. Among authors: lozano t. Cancer Res. 2017 Jul 1;77(13):3672-3684. doi: 10.1158/0008-5472.CAN-17-0236. Epub 2017 May 18. Cancer Res. 2017. PMID: 28522749
Targeting the extra domain A of fibronectin for cancer therapy with CAR-T cells.
Martín-Otal C, Lasarte-Cia A, Serrano D, Casares N, Conde E, Navarro F, Sánchez-Moreno I, Gorraiz M, Sarrión P, Calvo A, De Andrea CE, Echeveste J, Vilas A, Rodriguez-Madoz JR, San Miguel J, Prosper F, Hervas-Stubbs S, Lasarte JJ, Lozano T. Martín-Otal C, et al. Among authors: lozano t. J Immunother Cancer. 2022 Aug;10(8):e004479. doi: 10.1136/jitc-2021-004479. J Immunother Cancer. 2022. PMID: 35918123 Free PMC article.
Searching for the Achilles Heel of FOXP3.
Lozano T, Casares N, Lasarte JJ. Lozano T, et al. Front Oncol. 2013 Dec 3;3:294. doi: 10.3389/fonc.2013.00294. Front Oncol. 2013. PMID: 24350059 Free PMC article. Review.
TCR-induced FOXP3 expression by CD8+ T cells impairs their anti-tumor activity.
Lozano T, Conde E, Martín-Otal C, Navarro F, Lasarte-Cia A, Nasrallah R, Alignani D, Gorraiz M, Sarobe P, Romero JP, Vilas A, Roychoudhuri R, Hervás-Stubbs S, Casares N, Lasarte JJ. Lozano T, et al. Cancer Lett. 2022 Mar 1;528:45-58. doi: 10.1016/j.canlet.2021.12.030. Epub 2021 Dec 29. Cancer Lett. 2022. PMID: 34973390
Id1 and PD-1 Combined Blockade Impairs Tumor Growth and Survival of KRAS-mutant Lung Cancer by Stimulating PD-L1 Expression and Tumor Infiltrating CD8+ T Cells.
Baraibar I, Roman M, Rodríguez-Remírez M, López I, Vilalta A, Guruceaga E, Ecay M, Collantes M, Lozano T, Alignani D, Puyalto A, Oliver A, Ortiz-Espinosa S, Moreno H, Torregrosa M, Rolfo C, Caglevic C, García-Ros D, Villalba-Esparza M, De Andrea C, Vicent S, Pío R, Lasarte JJ, Calvo A, Ajona D, Gil-Bazo I. Baraibar I, et al. Among authors: lozano t. Cancers (Basel). 2020 Oct 28;12(11):3169. doi: 10.3390/cancers12113169. Cancers (Basel). 2020. PMID: 33126649 Free PMC article.
90 results